Custom synthesis | Naphthyridine | Pyrimidine | Indoline |
CardioCerebral-Vasculars

Olmesartan Medoxomil 144689-63-4

Olmesartan Medoxomil 144689-63-4
Olmesartan medoxomil is an angiotensin II receptor antagonist which has been used for the treatment of high blood pressure. It was developed by Sankyo in 1995, and is sold under the trade name Benicar Olmecip(Cipla)Olsar (Unichem Laboratories). An ester prodrug, it is completely and rapidly hydrolyzed to the active acid form, olmesartan (RNH-6270).

Synonyms: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl-1H-Imidazole-5-carboxylic acid, (5-methyl -2-oxo-1,3-dioxol-4-yl) methyl ester;Benicar;OlmesartanC29H30N6O6;CS-866, 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2(1H-tetazol-5-yl)[1,1biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester;Oimesartan;4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylicacid(5-Methyl-2-oxo-1,3-dioxol-4-yl)methylester;CS-866;Olmesartan medoxomil
CAS: 144689-63-4
MF: C24H26N6O3
MW: 446.5
EINECS:
Mol File: 144689-63-4.mol

GMP for Olmesartan Medoxomil 144689-63-4 is available.

Disclaimer:Those products (Olmesartan Medoxomil 144689-63-4) patented are for lab analytical & research purposes only.